Equity Overview
Price & Market Data
Price: $0.0308
Daily Change: -$0.0016 / 5.19%
Range: $0.0289 - $0.0308
Market Cap: $2,901,993
Volume: 8,920
Performance Metrics
1 Week: 24.91%
1 Month: -55.92%
3 Months: -79.94%
6 Months: -54.88%
1 Year: -39.83%
YTD: -92.78%
Details
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.